News Results showing high efficacy and tolerable safety of Kortuc in several radioresistant cancer types were published in Molecular and Clinical Oncology. This shows KORTUC has potential to treat various types of cancer that are radioresistant Results of the clinical use of …
News KORTUC Inc. closed financing from SBI Investment to accelerate Pivotal Phase II study in UK and US Today KORTUC Inc. (KORTUC) ann …
News KORTUC Inc. started research collaboration with Okayama University on the tumor immunity by a novel radiosensitizer KORTUC Inc. announced today th …
News Results showing high efficacy of Kortuc in treating locally advanced or recurrent breast cancer were published in Molecular and Clinical Oncology. These predict a positive outcome of the current pivotal Phase 2 study The results of clinical resear …
News KORTUC’s basic research result of tumor reoxygenation was presented at ESTRO 2021 The result of a basic research …
News KORTUC Inc. closed financing from AXA Japan to accelerate Pivotal Phase II study of novel radiosensitizer for cancer radiotherapy Businesswire Today KORTUC Inc. …
News Rationale and outcome in various cancer types in clinical practices in Japan were presented at ENA At ENA 2020 (32nd EORTC-NCI-AA …